In a filing, Intellia Therapeutics Inc revealed its EVP, Chief Financial Officer Dulac Edward J III unloaded Company’s shares for reported $0.1 million on Jul 23 ’25. In the deal valued at $14.02 per share,7,462 shares were sold. As a result of this transaction, Dulac Edward J III now holds 106,062 shares worth roughly $1.33 million.
Then, Clark Eliana sold 1,022 shares, generating $10,036 in total proceeds. Upon selling the shares at $9.82, the EVP, Chief Technical Officer now owns 95,369 shares.
Before that, Dube Michael P sold 2,503 shares. Intellia Therapeutics Inc shares valued at $24,905 were divested by the VP, Chief Accounting Officer at a price of $9.95 per share. As a result of the transaction, Dube Michael P now holds 57,137 shares, worth roughly $0.71 million.
Wolfe Research upgraded its Intellia Therapeutics Inc [NTLA] rating to an Outperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. JP Morgan also remained covering NTLA and has decreased its forecast on February 28, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Goldman revised its rating on February 28, 2025. It rated NTLA as “a Sell” which previously was an “a Neutral”.
Price Performance Review of NTLA
On Tuesday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock fall -4.65% to $12.5. Over the last five days, the stock has lost -7.34%. Intellia Therapeutics Inc shares have fallen nearly -52.69% since the year began. Nevertheless, the stocks have risen 7.20% over the past one year. While a 52-week high of $27.27 was reached on 07/23/25, a 52-week low of $5.90 was recorded on 04/07/25.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 12.12, which if violated will result in even more drops to 11.75. On the upside, there is a resistance level at 13.03. A further resistance level may holdings at 13.57.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-07-15, dropping by -0.82 million shares to a total of 28.87 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 29.69 million shares. There was a decline of -2.85%, which implies that there is a negative sentiment for the stock.
